Response to Imatinib in e13a2 Versus e14a2 BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Saudi Patients

被引：1
|
作者：
Elbjeirami, Wafa M. [1 ]
Alabdulwahab, Amal S. [2 ]
Elsayed, Hussein G. [2 ]
Abdelghaffer, Nermeen Adel [2 ,3 ]
Elnagdi, Noha [4 ,5 ]
Al-Jedani, Hanadi [4 ]
Abd Allatif, Nahla [4 ,5 ]
Al Shaikh, Abdulaziz [4 ]
Al-Allaf, Faisal [1 ]
机构：
[1] Mol Diagnost Sect, Dept Lab & Blood Bank, King, WI, Saudi Arabia
[2] Dept Hematol, King, WI, Saudi Arabia
[3] Ain Shams Univ, Dept Hematol, Cairo, Egypt
[4] Hematol Sect, Dept Lab & Blood Bank, King, WI, Saudi Arabia
[5] Natl Canc Inst Cairo Univ, Dept Clin Pathol, Cairo, Egypt
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5453.5453
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5453
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript
    Lucas, Claire M.
    Harris, Robert J.
    Giannoudis, Athina
    Davies, Andrea
    Knight, Katy
    Watmough, Sarah J.
    Wang, Lihui
    Clark, Richard E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (10): : 1362 - 1367
  • [2] CHRONIC MYELOID LEUKAEMIA PATIENTS WITH THE E13A2 BCR-ABL TRANSCRIPT HAVE INFERIOR RESPONSE TO IMATINIB THAN E14A2 PATIENTS
    Lucas, C. M.
    Harris, R. J.
    Wang, L.
    Knight, K.
    Watmough, S. J.
    Clark, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 346 - 346
  • [3] Molecular response to imatinib is achieved faster in chronic myeloid leukemia (CML) patients harboring the e14a2 BCR-ABL fusion transcript compared to those harboring e13a2
    Hanfstein, B.
    Erben, P.
    Agrawal, M.
    Schnittger, S.
    Ernst, T.
    Schenk, T.
    Hofmann, W-K
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M. C.
    ONKOLOGIE, 2010, 33 : 145 - 145
  • [4] Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib - an Analysis of the German CML Study IV
    Hanfstein, Benjamin
    Erben, Philipp
    Saussele, Susanne
    Lauseker, Michael
    Proetel, Ulrike
    Haag, Sven
    Schnittger, Susanne
    Haferlach, Claudia
    Kolb, Hans-Jochem
    Krause, Stefan W.
    Nerl, Christoph
    Heim, Dominik
    Baerlocher, Gabriela M.
    Schubert, Joerg E. A.
    Einsele, Hermann
    Haenel, Mathias
    Dengler, Jolanta
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Pfirrmann, Markus
    Hasford, Joerg
    Hofmann, Wolf-Karsten
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Mueller, Martin C.
    BLOOD, 2011, 118 (21) : 1612 - 1612
  • [5] Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia
    Su, Yi-Jiun
    Kuo, Ming-Chung
    Chen, Tsai-Yun
    Wang, Ming-Chung
    Yang, Youngsen
    Ma, Ming-Chun
    Lin, Tung-Liang
    Lin, Tung-Huei
    Chang, Hung
    Teng, Chieh-Lin Jerry
    Hsiao, Pei-Ching
    Chen, Chih-Cheng
    Wang, Po-Nan
    Shih, Lee-Yung
    CANCER SCIENCE, 2022, 113 (10) : 3518 - 3527
  • [6] CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH E14A2 BCR-ABL FUSION TRANSCRIPT ACHIEVE A FASTER MAJOR MOLECULAR REMISSION (MMR) ON IMATINIB THAN THOSE EXPRESSING THE E13A2 TRANSCRIPT
    Hanfstein, B.
    Erben, P.
    Agrawal, M.
    Schnittger, S.
    Schenk, T.
    Ernst, T.
    Hofmann, W. K.
    Hehlmann, R.
    Hochhaus, A.
    Mueller, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 337 - 337
  • [7] Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
    Hanfstein, Benjamin
    Lauseker, Michael
    Hehlmann, Ruediger
    Saussele, Susanne
    Erben, Philipp
    Dietz, Christian
    Fabarius, Alice
    Proetel, Ulrike
    Schnittger, Susanne
    Haferlach, Claudia
    Krause, Stefan W.
    Schubert, Joerg
    Einsele, Hermann
    Haenel, Mathias
    Dengler, Jolanta
    Falge, Christiane
    Kanz, Lothar
    Neubauer, Andreas
    Kneba, Michael
    Stegelmann, Frank
    Pfreundschuh, Michael
    Waller, Cornelius F.
    Spiekermann, Karsten
    Baerlocher, Gabriela M.
    Pfirrmann, Markus
    Hasford, Joerg
    Hofmann, Wolf-Karsten
    Hochhaus, Andreas
    Mueller, Martin C.
    HAEMATOLOGICA, 2014, 99 (09) : 1441 - 1447
  • [8] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Sharma, Pratibha
    Kumar, Lalit
    Mohanty, Sujata
    Kochupillai, Vinod
    ANNALS OF HEMATOLOGY, 2010, 89 (03) : 241 - 247
  • [9] Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts
    Pratibha Sharma
    Lalit Kumar
    Sujata Mohanty
    Vinod Kochupillai
    Annals of Hematology, 2010, 89 : 241 - 247
  • [10] No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib
    Pfirrmann, Markus
    Evtimova, Dobromira
    Saussele, Susanne
    Castagnetti, Fausto
    Cervantes, Francisco
    Janssen, Jeroen
    Hoffmann, Verena S.
    Gugliotta, Gabriele
    Hehlmann, Ruediger
    Hochhaus, Andreas
    Hasford, Joerg
    Baccarani, Michele
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (05) : 843 - 850
12345